Risk factors for isolation of multi-drug resistant organisms in coronavirus disease 2019 pneumonia: A multicenter study

Son, Hyo-Ju; Kim, Tark; Lee, Eunjung; Park, Se Yoon; Yu, Seong Jin; Hong, Hyo-Lim; Kim, Min‐Chul; Hong, Sun In; Bae, Seongman; Kim, Min Jae; Kim, Sung-Han; Yun, Ji Hyun; Jo, Kyeong Min; Lee, Yu‐Mi; Lee, Seungjae; Park, Jung Wan; Jeon, Min Hyok; Kim, Tae Hyong; Choo, Eun Ju

doi:10.1016/j.ajic.2021.06.005

Cited by 20 publications

(16 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these 28 included studies, 22 were case reports (describing single patients with individual data), two were case series (describing 7–42 patients with aggregate data), and four were cohort studies (describing 4–40 patients with aggregate data). Countries of study publication included the United States (n = 7) [ 7 , 9 , 21 – 25 ], Italy (n = 7) [ 26 – 32 ], Japan (n = 2) [ 33 , 34 ], Iran (n = 2) [ 35 , 36 ], the United Kingdom (n = 2) [ 37 , 38 ], Spain (n = 2) [ 39 , 40 ], Bahrain (n = 1) [ 41 ], China (n = 1) [ 42 ], France (n = 1) [ 43 ], the Philippines (n = 1) [ 44 ], Korea (n = 1) [ 45 ], and Canada (n = 1) [ 46 ], with publication dates ranging from April 15, 2020 to June 16, 2021. Table 1 describes the characteristics of these included studies and available information on their respective patient demographics in detail.…”

Section: Resultsmentioning

confidence: 99%

Clinical outcomes in patients co-infected with COVID-19 and Staphylococcus aureus: a scoping review

et al. 2021

View full text Add to dashboard Cite

Background Endemic to the hospital environment, Staphylococcus aureus (S. aureus) is a leading bacterial pathogen that causes deadly infections such as bacteremia and endocarditis. In past viral pandemics, it has been the principal cause of secondary bacterial infections, significantly increasing patient mortality rates. Our world now combats the rapid spread of COVID-19, leading to a pandemic with a death toll greatly surpassing those of many past pandemics. However, the impact of co-infection with S. aureus remains unclear. Therefore, we aimed to perform a high-quality scoping review of the literature to synthesize the existing evidence on the clinical outcomes of COVID-19 and S. aureus co-infection. Methods A scoping review of the literature was conducted in PubMed, Scopus, Ovid MEDLINE, CINAHL, ScienceDirect, medRxiv, and the WHO COVID-19 database using a combination of terms. Articles that were in English, included patients infected with both COVID-19 and S. aureus, and provided a description of clinical outcomes for patients were eligible. From these articles, the following data were extracted: type of staphylococcal species, onset of co-infection, patient sex, age, symptoms, hospital interventions, and clinical outcomes. Quality assessments of final studies were also conducted using the Joanna Briggs Institute’s critical appraisal tools. Results Searches generated a total of 1922 publications, and 28 articles were eligible for the final analysis. Of the 115 co-infected patients, there were a total of 71 deaths (61.7%) and 41 discharges (35.7%), with 62 patients (53.9%) requiring ICU admission. Patients were infected with methicillin-sensitive and methicillin-resistant strains of S. aureus, with the majority (76.5%) acquiring co-infection with S. aureus following hospital admission for COVID-19. Aside from antibiotics, the most commonly reported hospital interventions were intubation with mechanical ventilation (74.8 %), central venous catheter (19.1 %), and corticosteroids (13.0 %). Conclusions Given the mortality rates reported thus far for patients co-infected with S. aureus and COVID-19, COVID-19 vaccination and outpatient treatment may be key initiatives for reducing hospital admission and S. aureus co-infection risk. Physician vigilance is recommended during COVID-19 interventions that may increase the risk of bacterial co-infection with pathogens, such as S. aureus, as the medical community’s understanding of these infection processes continues to evolve.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical outcomes in patients co-infected with COVID-19 and Staphylococcus aureus: a scoping review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Together with the impact on manpower, there has been a major pressure on the emergence and spread of resistance. In hospitalised patients in Korea, multi-drug resistant organisms were found in 8.6% of patients and were more common in those receiving treatment with steroids [ 19 ]. In a point prevalence survey in Scotland, one third of 820 hospitalised patients with COVID-19 received an antibiotic for respiratory infection on the day of the survey.…”

Section: Discussionmentioning

confidence: 99%

Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality

Chan

O'Connor

Martyn

et al. 2022

Journal of Hospital Infection

View full text Add to dashboard Cite

“…Overall, 19/42 blood isolates were MRSA (45%), but no details were provided on how many were isolated from the eight patients who also had pneumonia [ 31 ]. In a multicenter, retrospective study conducted by Son et al in South Korea, 47 patients had available culture results among 152 hospitalized patients with COVID-19 (31%) [ 32 ]. Of them, 3/47 had respiratory cultures positive for MRSA (6%) [ 32 ].…”

Section: Studies Reporting On the Epidemiology Of Staphyloc...mentioning

confidence: 99%

“…In a multicenter, retrospective study conducted by Son et al in South Korea, 47 patients had available culture results among 152 hospitalized patients with COVID-19 (31%) [ 32 ]. Of them, 3/47 had respiratory cultures positive for MRSA (6%) [ 32 ]. In a single center, cross-sectional study of 43 hospitalized patients in Iran with COVID-19 and positive bacterial cultures, 6/43 patients had cultures positive for MRSA (14%), with two being cultures of respiratory specimens [ 33 ].…”

Section: Studies Reporting On the Epidemiology Of Staphyloc...mentioning

confidence: 99%

Methicillin-resistant Staphylococcus aureus lung infection in coronavirus disease 2019: how common?

Bassetti

Magnasco

Vena

et al. 2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Some patients with coronavirus disease 2019 (COVID-19) may develop pulmonary bacterial coinfection or superinfection, that could unfavorably impact their prognosis. Recent findings The exact burden of methicillin-resistant Staphylococcus aureus ( MRSA) lung infection in peculiar populations such as patients with COVID-19 remains somewhat elusive, possibly because of wide heterogeneity in methods and endpoints across studies. Summary There was important heterogeneity in the retrieved literature on the epidemiology of MRSA lung infection in patients with COVID-19, both when considering all other bacteria as the denominator (relative prevalence ranging from 2% to 29%) and when considering only S. aureus as the denominator (relative prevalence ranging from 11% to 65%). Overall, MRSA is among the most frequent causative agents of pulmonary infection in patients with COVID-19. Improving our ability to rapidly reach etiological diagnosis of bacterial lung infection in COVID-19 patients remains fundamental if we are to improve the rates of appropriate antibiotic therapy in patients with COVID-19 and concomitant/superimposed MRSA infection, at the same time avoiding antibiotic overuse in line with antimicrobial stewardship principles.

show abstract

Risk factors for isolation of multi-drug resistant organisms in coronavirus disease 2019 pneumonia: A multicenter study

Cited by 20 publications

References 36 publications

Clinical outcomes in patients co-infected with COVID-19 and Staphylococcus aureus: a scoping review

Clinical outcomes in patients co-infected with COVID-19 and Staphylococcus aureus: a scoping review

Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality

Methicillin-resistant Staphylococcus aureus lung infection in coronavirus disease 2019: how common?

Contact Info

Product

Resources

About